All Articles

In the phase 3 ASCENT study, Trodelvy was demonstrated to significantly enhance quality of life compared with standard of care in second-line and beyond metastatic triple-negative breast cancer.

Patients need to know why they are taking Trodelvy, the indications for which include metastatic triple-negative breast cancer. They should be educated on the benefits of Trodelvy along with potential side effects associated with treatment, including guidance on how they can manage those adverse events.

Trodelvy Access Support is a patient access and reimbursement support program that will help you and your patients understand reimbursement and specific coverage guidelines for Trodelvy.

Trodelvy has impressed a number of key opinion leaders across the breast cancer community based on its results in extending overall survival and progression-free survival in patients with metastatic triple-negative breast cancer who have received ≥2 prior therapies, ≥1 in the metastatic setting. It is becoming a preferred therapy for second-line and later metastatic triple-negative breast cancer treatment.

The results of a randomized, double-blind phase 3 study established the equivalence of bevacizumab reference to its biosimilar MIL60 in terms of clinical efficacy, safety, population pharmacokinetics, and immunogenicity in patients with nonsquamous NSCLC.

The results of a noninterventional, retrospective study showed that rituximab originator and the rituximab-abbs biosimilars yielded comparable efficacy and tolerability in the first-line treatment of patients with CLL and NHL, with rituximab-abbs use resulting in cost-savings.

Findings from modeling studies support adjuvant continuation of pertuzumab plus trastuzumab for patients achieving pathologic complete response among patients with high-risk, HER2-positive early breast cancer.